CRISPR Therapeutics (CRSP) vs Denali Therapeutics (DNLI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Denali Therapeutics (DNLI) has outperformed CRISPR Therapeutics (CRSP) over the past year, gaining 2.5% versus a loss of 22.2%. Over five years, CRSP leads with a -50.4% price change compared with -59.0% for DNLI. CRISPR Therapeutics is the larger company by market cap ($3.79 billion vs $2.96 billion), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CRSP | DNLI |
|---|---|---|
| Share price | $39.10 | $18.45 |
| Market cap | $3.79B | $2.96B |
| 1-day change | +0.44% | +1.37% |
| YTD return | -25.44% | +11.75% |
| 1-year return | -22.16% | +2.50% |
| 5-year return | -50.37% | -59.02% |
| EPS (TTM) | $-4.73 | $-1.72 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $3.51M | $0 |
| Revenue growth (YoY) | -90.59% | — |
| Net income (latest FY) | $-581.60M | $-512.54M |
| Operating margin | -18933.65% | — |
| Net margin | -16569.77% | — |
| 52-week high | $63.45 | $27.30 |
| 52-week low | $38.15 | $15.34 |
| Distance from 52-week high | -38.38% | -32.42% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +118.47% | +94.15% |
| Average volume | 1.74M | 1.68M |
| Shares outstanding | 97.00M | 160.29M |
| Employees | — | 503 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- DNLI has outperformed CRSP by 24.7 percentage points over the past year.
About CRISPR Therapeutics
CRSP stock →CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company's CRISPR/Cas9 is a technology for gene editing which is the process of precisely altering specific sequences of genomic DNA.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
About Denali Therapeutics
DNLI stock →Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome).
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 503 employees
CRSP vs DNLI FAQ
Which is bigger, CRISPR Therapeutics or Denali Therapeutics?
CRISPR Therapeutics (CRSP) is larger, with a market capitalization of $3.79B compared with $2.96B for Denali Therapeutics (DNLI).
Which stock has performed better over the past year, CRSP or DNLI?
DNLI returned +2.50% over the past 12 months, compared with -22.16% for CRSP (price return, excluding dividends). Past performance does not predict future results.
Are CRISPR Therapeutics and Denali Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.